Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
Summary not available.
Summary not available.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reiterated its board's unanimous recommendation that stockholders vote FOR the merger with Alcon on the white proxy card.
Key points: Alcon's offer is $28.00 per share in cash (a 59% premium to the 90-day VWAP). STAAR contrasts this with Broadwood's position and a prior price of $18.49 per share, warning a vote against could invite control shifts and valuation pressure. Stockholders are urged to contact STAAR's proxy solicitor for voting assistance.
Summary not available.
Defender Capital, a long-term shareholder owning approximately 1.5% of STAAR Surgical (NASDAQ: STAA), announced on October 7, 2025 its opposition to the proposed sale of STAAR to Alcon (NYSE: ALC) for $28 per share. Defender said the $28 price significantly undervalues STAAR, noting the STAAR board rejected a prior $58 per share cash offer from Alcon sixteen months earlier. Defender cited recent positive projections and outlook from STAAR management and argued there is no compelling reason to sell at the proposed valuation. Defender described the transaction as ill-advised and said it does not reflect STAAR’s standalone prospects.
Yunqi Capital (NASDAQ:STAA), a 5.1% shareholder, reiterated opposition to STAAR Surgical’s proposed sale to Alcon announced Aug 5, 2025, arguing the deal undervalues STAAR and mischaracterizes its China outlook.
Yunqi says recent revenue weakness (~10% decline 2023–2025) was driven by temporary China distributor inventory corrections (quarterly China revenue drops of 82%, 99%, 92% in late 2024–mid 2025) and that inventory has returned to historical levels per STAAR’s 10-Q. Yunqi highlights rising operating expenses (annualized run-rate from ~$150M in 2022 to ~$250M in 2024), U.S. headcount growth (~+400), and CEO merger-related payouts (~$24M of ~$55M total) as concerns. Yunqi proposes cost cuts, channel fixes and buybacks to unlock value instead of the sale.
Summary not available.
STAAR (NASDAQ: STAA) highlighted independent industry analyst commentary endorsing its proposed cash merger with Alcon at $28 per share. Analysts cite a ~59% premium to STAAR’s 90‑day VWAP, an implied total equity value of ~$1.5 billion and multiples ranging from ~4.7x FY26 sales to ~6x 2025 sales. STAAR warned of sustained standalone risks driven by severe China weakness (China revenue fell to $5.3M, -92% Y/Y) and channel inventory issues. The STAAR Board unanimously recommends voting “FOR” the merger at a special meeting on October 23, 2025.
STAAR Surgical (NASDAQ: STAA) urged stockholders to vote FOR the proposed merger with Alcon, saying the deal delivers $28 per share in cash and a 59% premium to STAAR's 90‑day VWAP (and a 51% premium to the Aug 4, 2025 close). The Board unanimously recommended the merger and says the process was thorough, rejecting Broadwood Partners’ criticisms as flawed and misleading.
STAAR highlighted material headwinds: net sales have declined since 2023, China represented 51% of net sales, Q2 2025 showed a $16.8M net loss, and management projects 10% annual net‑sales growth (2026–2030). Closing is expected in ~6–12 months, subject to regulatory and shareholder approval.